Tenon Medical, Inc. Research and Development Expense
Tenon Medical, Inc. (TNON) reported Research and Development Expense of $768.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Tenon Medical, Inc. research and development expense for the quarter ending 2026-06-30 was $768.00K, a 52.68% increase year-over-year.
- Tenon Medical, Inc. research and development expense for the quarter ending 2026-03-31 was $662.00K, a 4.20% decline year-over-year.
- Tenon Medical, Inc. research and development expense for the quarter ending 2025-12-31 was $527.00K, a 7.38% decline year-over-year.
- Tenon Medical, Inc. research and development expense for the quarter ending 2025-09-30 was $428.00K, a 34.86% decline year-over-year.
- Tenon Medical, Inc. research and development expense for fiscal 2025 was $2.15M, a 17.44% decline from fiscal 2024.
- Tenon Medical, Inc. research and development expense for fiscal 2024 was $2.60M, a 17.70% decline from fiscal 2023.
- Tenon Medical, Inc. research and development expense for fiscal 2023 was $3.16M, a 11.85% increase from fiscal 2022.
- Tenon Medical, Inc. research and development expense for fiscal 2022 was $2.83M, a 64.61% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $768.00K 10-Q · filed 2026-08-13 | $1.43M 10-Q · filed 2026-08-13 | $1.96M derived: sum of 3 quarters · filed 2026-08-13 | $2.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $662.00K 10-Q · filed 2026-05-15 | $1.19M derived: sum of 2 quarters · filed 2026-05-15 | $1.62M derived: sum of 3 quarters · filed 2026-05-15 | $2.12M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $527.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $955.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.46M derived: sum of 3 quarters · filed 2026-08-13 | $2.15M 10-K · filed 2026-03-27 |
| 2025-09-30 | $428.00K 10-Q · filed 2025-11-13 | $931.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.62M 10-Q · filed 2025-11-13 | $2.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $503.00K 10-Q · filed 2026-08-13 | $1.19M 10-Q · filed 2026-08-13 | $1.76M derived: sum of 3 quarters · filed 2026-08-13 | $2.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $691.00K 10-Q · filed 2026-05-15 | $1.26M derived: sum of 2 quarters · filed 2026-05-15 | $1.92M derived: sum of 3 quarters · filed 2026-05-15 | $2.63M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $569.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.23M derived: sum of 2 quarters · filed 2026-03-27 | $1.93M derived: sum of 3 quarters · filed 2026-03-27 | $2.60M 10-K · filed 2026-03-27 |
| 2024-09-30 | $657.00K 10-Q · filed 2025-11-13 | $1.36M derived: sum of 2 quarters · filed 2025-11-13 | $2.03M 10-Q · filed 2025-11-13 | $2.73M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $708.00K 10-Q · filed 2025-08-13 | $1.38M 10-Q · filed 2025-08-13 | $2.07M derived: sum of 3 quarters · filed 2025-08-13 | $2.81M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $669.00K 10-Q · filed 2025-05-13 | $1.36M derived: sum of 2 quarters · filed 2025-05-13 | $2.10M derived: sum of 3 quarters · filed 2025-05-13 | $3.00M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $691.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $1.43M derived: sum of 2 quarters · filed 2025-03-26 | $2.33M derived: sum of 3 quarters · filed 2025-03-26 | $3.16M 10-K · filed 2025-03-26 |
| 2023-09-30 | $737.00K 10-Q · filed 2024-11-14 | $1.64M derived: sum of 2 quarters · filed 2024-11-14 | $2.47M 10-Q · filed 2024-11-14 | $3.28M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $901.00K 10-Q · filed 2024-08-13 | $1.74M 10-Q · filed 2024-08-13 | $2.55M derived: sum of 3 quarters · filed 2024-08-13 | $3.34M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $834.00K 10-Q · filed 2024-05-15 | $1.65M derived: sum of 2 quarters · filed 2024-05-15 | $2.44M derived: sum of 3 quarters · filed 2024-05-15 | $3.10M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $812.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.61M derived: sum of 2 quarters · filed 2024-03-29 | $2.27M derived: sum of 3 quarters · filed 2024-03-29 | $2.83M 10-K · filed 2024-03-29 |
| 2022-09-30 | $797.00K 10-Q · filed 2023-11-14 | $1.45M derived: sum of 2 quarters · filed 2023-11-14 | $2.02M 10-Q · filed 2023-11-14 | $2.81M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $657.00K 10-Q · filed 2023-08-11 | $1.22M 10-Q · filed 2023-08-11 | $2.01M derived: sum of 3 quarters · filed 2023-08-11 | $2.61M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $562.00K 10-Q · filed 2023-05-09 | $1.35M derived: sum of 2 quarters · filed 2023-05-09 | $1.96M derived: sum of 3 quarters · filed 2023-05-09 | $2.19M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $793.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $1.39M derived: sum of 2 quarters · filed 2023-03-10 | $1.63M derived: sum of 3 quarters · filed 2023-03-10 | $1.72M 10-K · filed 2023-03-10 |
| 2021-09-30 | $601.00K 10-Q · filed 2022-11-10 | $838.00K derived: sum of 2 quarters · filed 2022-11-10 | $925.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $237.00K 10-Q · filed 2022-08-12 | $324.00K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $87.00K 10-Q · filed 2022-06-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |